Immungenetics AG is a fast advancing private company in the clinical-stage. We are developing drugs for a wide variety of devastating, untreatable diseases. Investors may be interested in initiating conversations with us, ahead of financial rounds and capital actions.
An important part of our ambitious drug development strategy is to enter strategic alliances with pharmaceutical companies in order to bring more effective treatments to the clinic, faster. We are open to discuss collaborations and milestone-based licensing agreements for our programmes, as well as potential partnerships that may be of mutual interest.
You are welcome to contact us.
Mr. Antonio Martinez Arbizu
Chief Executive Officer